Suministro de Aflibercept (DOE) Intravítreo 40 mg/ml
TED · 736776-2026Award noticeNo deadline given
Buyer
NameOSAKIDETZA - Servicio Vasco de Salud - Organización Central
CountryES
Published2026-10-23
Deadline—
Value
Estimated€16,161,600 · 16,161,600 EUR
Awarded€3,108,000 · 3,108,000 EUR
Who already wins at this buyer
Firms with recorded awards from OSAKIDETZA - Servicio Vasco de Salud - Organización Central in this tender’s CPV categories — the incumbents you are bidding against.
| Firm | Wins | Awarded | Last win |
|---|---|---|---|
| ASTRAZENECA FARMACEUTICA SPAIN, S.A. | 6 | €14,614,191 | 2026-10-22 |
| PFIZER, S.L. | 5 | €67,637,810 | 2026-10-09 |
| EDWARDS LIFESCIENCIES, S.L. | ABBOTT MEDICAL ESPAÑA SA | MEDTRONIC IBÉRICA, S.A. | BOSTON SCIENTIFIC IBÉRICA, S.A. | MERCÉ V. ELECTROMEDICINA, S.L. | PALEX MEDICAL | SAGITTAE MEDICAL S.L | SERMEBI 97 SL | 5 | €40,141,054 | 2026-09-18 |
| TAKEDA FARMACÉUTICA ESPAÑA, S.A. | 5 | €10,796,370 | 2026-10-16 |
| ROCHE FARMA, S.A. UNIPERSONAL | 4 | €130,837,823 | 2026-09-08 |
CPV codes
33600000 Medical equipment & pharmaceuticalsDescription
Suministro de Aflibercept (DOE) Intravítreo 40 mg/ml
Similar tenders
Closest by meaning — across languages, via embeddings.
| Published | Title | Buyer | Match |
|---|---|---|---|
| 2026-06-22 | Suministro de Aflibercept (DOE) Intravítreo 40 mg/ml | OSAKIDETZA - Servicio Vasco de Salud - Organización Central ES | 100% |
| 2026-06-22 | Suministro de Infliximab (DOE) | OSAKIDETZA - Servicio Vasco de Salud - Organización Central ES | 95% |
| 2026-05-20 | Suministro de Tirotropina Alfa (DOE) | OSAKIDETZA - Servicio Vasco de Salud - Organización Central ES | 95% |
| 2026-07-15 | Suministro de Abrocitinib (DOE) | OSAKIDETZA - Servicio Vasco de Salud - Organización Central ES | 95% |
| 2026-06-17 | Suministro de Acetilcisteína (DOE) Inyectable 100 MG/ML | OSAKIDETZA - Servicio Vasco de Salud - Organización Central ES | 95% |
| 2026-05-28 | Suministro de Sebelipasa Alfa (DOE) | OSAKIDETZA - Servicio Vasco de Salud - Organización Central ES | 95% |